scholarly journals Severe Lymphopenia and Related T-cell Immunity in an Avian Influenza A (H7N9)-Infected Patient

2018 ◽  
Vol 131 (22) ◽  
pp. 2765-2766
Author(s):  
Nan-Nan Zhang ◽  
Yi Zhang ◽  
Jin-Gen Xia ◽  
Min Li ◽  
Xu Huang ◽  
...  
2018 ◽  
Vol 92 (17) ◽  
Author(s):  
Min Zhao ◽  
Junbo Chen ◽  
Shuguang Tan ◽  
Tao Dong ◽  
Hui Jiang ◽  
...  

ABSTRACT Since 2013, influenza A H7N9 virus has emerged as the most common avian influenza virus subtype causing human infection, and it is associated with a high fatality risk. However, the characteristics of immune memory in patients who have recovered from H7N9 infection are not well understood. We assembled a cohort of 45 H7N9 survivors followed for up to 15 months after infection. Humoral and cellular immune responses were analyzed in sequential samples obtained at 1.5 to 4 months, 6 to 8 months, and 12 to 15 months postinfection. H7N9-specific antibody concentrations declined over time, and protective antibodies persisted longer in severely ill patients admitted to the intensive care unit (ICU) and patients presenting with acute respiratory distress syndrome (ARDS) than in patients with mild disease. Frequencies of virus-specific gamma interferon (IFN-γ)-secreting T cells were lower in critically ill patients requiring ventilation than in patients without ventilation within 4 months after infection. The percentages of H7N9-specific IFN-γ-secreting T cells tended to increase over time in patients ≥60 years or in critically ill patients requiring ventilation. Elevated levels of antigen-specific CD8+ T cells expressing the lung-homing marker CD49a were observed at 6 to 8 months after H7N9 infection compared to those in samples obtained at 1.5 to 4 months. Our findings indicate the prolonged reconstruction and evolution of virus-specific T cell immunity in older or critically ill patients and have implications for T cell-directed immunization strategies. IMPORTANCE Avian influenza A H7N9 virus remains a major threat to public health. However, no previous studies have determined the characteristics and dynamics of virus-specific T cell immune memory in patients who have recovered from H7N9 infection. Our findings showed that establishment of H7N9-specific T cell memory after H7N9 infection was prolonged in older and severely affected patients. Severely ill patients mounted lower T cell responses in the first 4 months after infection, while T cell responses tended to increase over time in older and severely ill patients. Higher levels of antigen-specific CD8+ T cells expressing the lung-homing marker CD49a were detected at 6 to 8 months after infection. Our results indicated a long-term impact of H7N9 infection on virus-specific memory T cells. These findings advance our understanding of the dynamics of virus-specific memory T cell immunity after H7N9 infection, which is relevant to the development of T cell-based universal influenza vaccines.


2021 ◽  
Vol 11 ◽  
Author(s):  
Brock Kingstad-Bakke ◽  
Randall Toy ◽  
Woojong Lee ◽  
Pallab Pradhan ◽  
Gabriela Vogel ◽  
...  

Eliciting durable and protective T cell-mediated immunity in the respiratory mucosa remains a significant challenge. Polylactic-co-glycolic acid (PLGA)-based cationic pathogen-like particles (PLPs) loaded with TLR agonists mimic biophysical properties of microbes and hence, simulate pathogen-pattern recognition receptor interactions to safely and effectively stimulate innate immune responses. We generated micro particle PLPs loaded with TLR4 (glucopyranosyl lipid adjuvant, GLA) or TLR9 (CpG) agonists, and formulated them with and without a mucosal delivery enhancing carbomer-based nanoemulsion adjuvant (ADJ). These adjuvants delivered intranasally to mice elicited high numbers of influenza nucleoprotein (NP)-specific CD8+ and CD4+ effector and tissue-resident memory T cells (TRMs) in lungs and airways. PLPs delivering TLR4 versus TLR9 agonists drove phenotypically and functionally distinct populations of effector and memory T cells. While PLPs loaded with CpG or GLA provided immunity, combining the adjuvanticity of PLP-GLA and ADJ markedly enhanced the development of airway and lung TRMs and CD4 and CD8 T cell-dependent immunity to influenza virus. Further, balanced CD8 (Tc1/Tc17) and CD4 (Th1/Th17) recall responses were linked to effective influenza virus control. These studies provide mechanistic insights into vaccine-induced pulmonary T cell immunity and pave the way for the development of a universal influenza and SARS-CoV-2 vaccines.


2019 ◽  
Vol 20 (8) ◽  
pp. 1035-1045 ◽  
Author(s):  
Emily A. Hemann ◽  
Richard Green ◽  
J. Bryan Turnbull ◽  
Ryan A. Langlois ◽  
Ram Savan ◽  
...  

2014 ◽  
Vol 111 (3) ◽  
pp. 1049-1054 ◽  
Author(s):  
S. Quinones-Parra ◽  
E. Grant ◽  
L. Loh ◽  
T. H. O. Nguyen ◽  
K.-A. Campbell ◽  
...  

2014 ◽  
Vol 212 (1) ◽  
pp. 86-94 ◽  
Author(s):  
Katherine A. Richards ◽  
Jennifer Nayak ◽  
Francisco A. Chaves ◽  
Anthony DiPiazza ◽  
Zackery A. G. Knowlden ◽  
...  

2018 ◽  
Vol 9 ◽  
Author(s):  
Zeb R. Zacharias ◽  
Kathleen A. Ross ◽  
Emma E. Hornick ◽  
Jonathan T. Goodman ◽  
Balaji Narasimhan ◽  
...  

2010 ◽  
Vol 107 (28) ◽  
pp. 12599-12604 ◽  
Author(s):  
Stephanie Gras ◽  
Lukasz Kedzierski ◽  
Sophie A. Valkenburg ◽  
Karen Laurie ◽  
Yu Chih Liu ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. e91273 ◽  
Author(s):  
Venkata R. Duvvuri ◽  
Bhargavi Duvvuri ◽  
Christilda Alice ◽  
Gillian E. Wu ◽  
Jonathan B. Gubbay ◽  
...  

Virology ◽  
2002 ◽  
Vol 299 (1) ◽  
pp. 100-108 ◽  
Author(s):  
A.C.M. Boon ◽  
E. Fringuelli ◽  
Y.M.F. Graus ◽  
R.A.M. Fouchier ◽  
K. Sintnicolaas ◽  
...  

2020 ◽  
Author(s):  
Brock Kingstad-Bakke ◽  
Randall Toy ◽  
Woojong Lee ◽  
Pallab Pradhan ◽  
Gabriela Vogel ◽  
...  

ABSTRACTEliciting durable and protective T cell-mediated immunity in the respiratory mucosa remains a significant challenge. Polylactic-co-glycolic acid (PLGA)-based cationic pathogen-like particles (PLPs) loaded with TLR agonists mimic biophysical properties of microbes and hence, simulate pathogen-pattern recognition receptor interactions to safely and effectively stimulate innate immune responses. We generated micro particle PLPs loaded with TLR4 (glucopyranosyl lipid adjuvant, GLA) or TLR9 (CpG) agonists, and formulated them with and without a mucosal delivery enhancing carbomer-based nanoemulsion adjuvant (ADJ). These adjuvants delivered intranasally to mice elicited high numbers of influenza nucleoprotein (NP)-specific CD8+/ CD4+ effector and tissue-resident memory T cells (TRMs) in lungs and airways. PLPs delivering TLR4 versus TLR9 agonists drove phenotypically and functionally distinct populations of effector and memory T cells. While PLPs loaded with CpG or GLA provided immunity, combining the adjuvanticity of PLP-GLA and ADJ synergistically enhanced the development of airway and lung TRMs and protective immunity to pathogenic influenza A virus. Further, balanced CD8 (Tc1/Tc17) and CD4 (Th1/Th17) recall responses were linked to effective influenza virus control in the lungs. These studies provide mechanistic insights into vaccine-induced T cell immunity in the respiratory tract and pave the way for the development of a universal influenza vaccine.


Sign in / Sign up

Export Citation Format

Share Document